Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. - Wikidata - wikimedia - TriplyDB

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.

http://www.wikidata.org/entity/Q35076802

about

Current Landscape of Antiviral Drug Discovery Clinical Implications of Antiviral Resistance in Influenza The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design Chemical Genomics Identifies the PERK-Mediated Unfolded Protein Stress Response as a Cellular Target for Influenza Virus Inhibition Progress of small molecular inhibitors in the development of anti-influenza virus agents.The pharmacological management of severe influenza infection - 'existing and emerging therapies'.The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism.The cap-binding site of influenza virus protein PB2 as a drug target.A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro Influenza antivirals currently in late-phase clinical trial.Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis.Novel Polyanions Inhibiting Replication of Influenza Viruses.A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication.Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.Antiviral therapy for respiratory viral infections in immunocompromised patients.Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit.Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.Molecular Basis of mRNA Cap Recognition by Influenza B Polymerase PB2 Subunit.Current landscape and future prospects of antiviral drugs derived from microbial products.Protein-Structure Assisted Optimization of 4,5-Dihydroxypyrimidine-6-Carboxamide Inhibitors of Influenza Virus Endonuclease.Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors.Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza.Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017

P2860

Q26766639-87AC5B55-6763-4980-990E-1D1D8D6D33EC Q26782746-5A427DA9-59F2-4526-8388-99D9B044B9CD Q28071809-A272683B-84CB-4F3F-99BD-600EE573F576 Q28833828-27ED46F2-0783-4BB3-B453-B7B3A3775517 Q30234943-83E8A487-93E2-4048-B126-CBA7AC32CFE9 Q30243907-4A089C27-6409-4A1E-96C8-1AD7F0CD9040 Q30371858-59DC217D-82B4-4A2A-8CE3-FAEB7D9D1D65 Q30384645-533FC80F-025D-4C37-AB44-CA65E7FA3E04 Q30390167-6817CFFB-C3DC-4C9E-B815-7A2D3234A750 Q30398099-8B11E419-DC98-4EE3-BC00-BFDFEC6A0053 Q30398601-C8A30764-106E-4A7F-A486-DFB61B9BE5F8 Q30791826-1160C79C-71DF-4073-B401-C4B36929ADCA Q36730039-78A8090A-4F3F-4C66-8809-B5F2057C0ABC Q38766044-5B9FB29A-5893-4BE9-B8AA-A9F1445B0936 Q38912274-99026816-34D8-4373-A126-0D60B004E1CD Q38963385-5468C89E-7C59-46A9-9A62-D228DA490178 Q39076394-FC2013E0-2B6F-438F-8367-8358D546DEBD Q40058871-0BB1A8C9-1B13-4C0A-A381-DFD459441D47 Q40071053-99B16ADD-A91C-4FAD-91DA-68FB0260C6F8 Q40743239-621E1BCA-5A10-4E01-AAF2-3C281B0FFF7E Q41130389-E1DB4C45-E7C7-4F51-AD2F-F86E3903F643 Q41919714-48817551-3EFE-40C2-8188-F8ED26C249EF Q45323667-84134C3C-B3B7-4D52-B23C-D85A2702C0FD Q47264095-AB3B2825-249E-4668-A8BE-21E8EA244FAB Q47549703-2A936C24-2A28-4F26-947D-BE607A2C6FA8 Q47569878-E8AA82B8-7D1E-4762-ACD2-14EDD3F435FE Q47601706-5805173E-26CC-490B-A7C3-FD99F0D35586 Q54223806-9464F473-5FC8-471A-820D-EA1F022C9985 Q55426854-F787A2B8-DC20-483D-9A35-4C41A1ADA382 Q56969102-02D43DDA-E513-49A9-BBA4-C9B5F53B8D38

P2860

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.

http://www.wikidata.org/entity/Q35076802

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.

@ast

Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.

@en

type

label

Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.

@ast

Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.

@en

prefLabel

Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.

@ast

Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.

@en

P1433

Q35076802-2C313C4D-A976-4D2E-B443-7C2FA105C437

P1476

Q35076802-F600857C-5E09-4F12-9037-6E71FE875301

P2093

Q35076802-253D11C6-B913-4A37-9459-06078BEA887F

Q35076802-31D54B13-247A-43DF-9044-E9D61B6DAD21

Q35076802-3A836185-E988-46DE-A57A-55D4EF138259

Q35076802-3D169BAB-7D57-4066-B784-8ED7201A3505

Q35076802-43D9DEB0-256E-499F-9440-EFA88A22B03A

Q35076802-45D42E00-F510-49BB-B899-D0524A90C998

Q35076802-4BC091FB-6149-4823-9A2B-021987825966

Q35076802-4F6D0E31-A806-4A09-A677-397B670BBC06

Q35076802-7828487C-86DB-487C-B271-264963984441

Q35076802-82639546-783E-4121-915A-03A4AF39951E

P2860

Q35076802-03F4861A-16B9-429A-AD78-43666BC90AE7

Q35076802-0696A08B-8071-4BE7-B216-B3FE4DB66E2A

Q35076802-094D963E-C325-46C3-9EF5-DDB5CD781D42

Q35076802-0AC86464-CEC9-4A2B-B375-B65AE96488B8

Q35076802-0B37492D-8954-4C57-969D-16A05F94247E

Q35076802-0F6CA12C-6C5A-4086-94F8-B558E3F33E6F

Q35076802-131EE34F-C236-4B7E-9725-34BD9747F597

Q35076802-18473F96-E6A0-4B47-8FD0-C3F2D5FA8BD3

Q35076802-194A69FC-4C4E-42BF-A7CB-018B1543AF28

Q35076802-195850FD-4944-4A6B-8315-560C7EE7F106

P304

Q35076802-FAF4E8D3-191F-4EB4-AA1E-D4EE2E85CA23

P31

Q35076802-F197100E-EBAE-4ADB-98B9-323F71CEB234

P356

Q35076802-19F25445-E97A-468F-9C79-F21ECC014BE0

P407

Q35076802-E724F6B7-E9C5-44E9-99A6-3E0E01435490

P433

Q35076802-EDFE044F-DF17-4E6F-ABDF-DF95203C9DF2

P478

Q35076802-4084859A-C23B-44B5-92B7-55DB90011B8B

P577

Q35076802-2243BA8D-CA8F-456D-B71B-7B11D8CE79B9

P698

Q35076802-5912E315-6AA9-4BE9-99A6-88AA052C5D7F

P932

Q35076802-9B4C7653-93B7-4E64-81DE-752B71B0FA69

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.

@en

P2093

Alice W Tsai

http://www.w3.org/2001/XMLSchema#string

Ann D Kwong

http://www.w3.org/2001/XMLSchema#string

Azin Nezami

http://www.w3.org/2001/XMLSchema#string

Chris Bral

http://www.w3.org/2001/XMLSchema#string

Colleen F McNeil

http://www.w3.org/2001/XMLSchema#string

Emanuele Perola

http://www.w3.org/2001/XMLSchema#string

Hamilton B Bennett

http://www.w3.org/2001/XMLSchema#string

Joshua R Leeman

http://www.w3.org/2001/XMLSchema#string

Kumkum Saxena

http://www.w3.org/2001/XMLSchema#string

Marc D Jacobs

http://www.w3.org/2001/XMLSchema#string

P2860

The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews

Systematic review of influenza resistance to the neuraminidase inhibitors

Neuraminidase inhibitors for preventing and treating influenza in adults and children

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome

Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)

Evolution of influenza A virus PB2 genes: implications for evolution of the ribonucleoprotein complex and origin of human influenza A virus

The structural basis for cap binding by influenza virus polymerase subunit PB2

Biological and Structural Characterization of a Host-Adapting Amino Acid in Influenza Virus

Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers

New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain

P304

1569-1582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.04623-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25547360

http://www.w3.org/2001/XMLSchema#string

P932

4325764

http://www.w3.org/2001/XMLSchema#string